To add to its autoimmune therapy area, which is currently dominated by the multi-blockbuster Humira® (adalimumab), AbbVie has entered into a global collaboration with Germany based Boehringer Ingelheim (BI) for the development and commercialization of BI’s Phase III psoriasis asset, risankizumab (BI 655066). Through the deal, BI will receive an initial upfront payment of US$595 M, and potential undisclosed milestone and royalty payments. In addition, through this collaboration AbbVie gains the option to further develop BI’s early-stage asset, BI 655064.